Literature DB >> 19369633

Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung.

Chih-Wei Wang1, Tzu-I Wu, Chih-Teng Yu, Yi-Cheng Wu, Yun-Hui Teng, Szu-Ying Chin, Chyong-Huey Lai, Tse-Ching Chen.   

Abstract

To date, there is no reliable immunohistochemical marker that discriminates between primary pulmonary squamous cell carcinoma (SCC) and cervical SCC metastatic to the lung. In this study, immunohistochemical staining of p16 was performed on 33 primary pulmonary SCCs, 48 primary cervical SCCs, and 17 cases of cervical SCC with pulmonary metastasis. Expression of p16 was noted in 47 cases of cervical SCC (47/48 [98%]), and all were strongly stained. Of the 7 cases of primary pulmonary SCC (7/33 [21%]) in which p16 expression was detected, 3 were weakly positive, 1 was moderately positive, and 3 were strongly positive. Among these p16+ pulmonary SCCs, only 1 showed detectable human papillomavirus DNA. Of the 17 cases of cervical SCC with pulmonary metastasis, all of the pulmonary and cervical tumors were positive for p16. p16 is a useful marker for the discrimination between cervical and pulmonary SCCs. The performance of p16 staining at different cutoff values was also compared.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369633     DOI: 10.1309/AJCPTPBC6V5KUITM

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.

Authors:  Takashi Murakami; Takuya Murata; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Igarashi; Ho Kyoung Hwang; Yukihiko Hiroshima; Chihiro Hozumi; Shin Komatsu; Takashi Kikuchi; Thinzar M Lwin; Jonathan C Delong; Kentaro Miyake; Yong Zhang; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  Anticancer Res       Date:  2017-01       Impact factor: 2.480

2.  Pulmonary lymphangitic carcinomatosis from squamous cell carcinoma of the cervix.

Authors:  Rani Kanthan; Jenna-Lynn B Senger; Dana Diudea
Journal:  World J Surg Oncol       Date:  2010-12-03       Impact factor: 2.754

3.  Diagnostic Usefulness of p16 Immunohistochemistry for some Epithelial Lesions in the Pathology Service of Sultan Qaboos University Hospital.

Authors:  Iman Al-Ghafri; Samia Al-Husseini; Afrah Al-Rashdi; Mohammad Arafa
Journal:  Maedica (Bucur)       Date:  2021-12

4.  Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern.

Authors:  Yukihiko Hiroshima; Yong Zhang; Nan Zhang; Ali Maawy; Sumiyuki Mii; Mako Yamamoto; Fuminari Uehara; Shinji Miwa; Shuya Yano; Takashi Murakami; Masashi Momiyama; Takashi Chishima; Kuniya Tanaka; Yasushi Ichikawa; Michael Bouvet; Takuya Murata; Itaru Endo; Robert M Hoffman
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

5.  Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models.

Authors:  Yukihiko Hiroshima; Yong Zhang; Ming Zhao; Nan Zhang; Takashi Murakami; Ali Maawy; Sumiyuki Mii; Fuminari Uehara; Mako Yamamoto; Shinji Miwa; Shuya Yano; Masashi Momiyama; Ryutaro Mori; Ryusei Matsuyama; Takashi Chishima; Kuniya Tanaka; Yasushi Ichikawa; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

6.  A Clinicopathological Review of Pulmonary Metastasis from Uterine Cervical Cancer.

Authors:  Eun Young Ki; Keun Ho Lee; Jong Sup Park; Soo Young Hur
Journal:  Cancer Res Treat       Date:  2015-02-23       Impact factor: 4.679

7.  Clinical Application of Next-generation Sequencing for the Diagnosis of Lung Squamous Cell Carcinoma: Is It Primary or Secondary?

Authors:  Hiroaki Aizawa; Takahiro Karasaki; Kazuhiro Nagayama; Aya Shinozaki-Ushiku; Hiroyuki Aburatani; Hiroyuki Mano; Jun Nakajima
Journal:  Intern Med       Date:  2020-02-12       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.